ARGX
argenx SE
NASDAQ · Healthcare · Biotechnology · NL
$1,033.15
−1.93%Year over year
Reported trailing growth
- Revenue
- +128.6%
- EBITDA
- +737.0%
- EBIT
- —
- EPS
- +609.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -76.9%
- EBITDA
- -70.2%
- EPS
- -77.7%
Three-year CAGR
- Revenue
- +116.2%
- EBITDA
- +1146.3%
- EBIT
- +4970.3%
- Net income
- +55.1%
- EPS
- +51.9%
- Free cash flow
- +659.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026